Revision Year: 2012 Publisher: ANFARM HELLAS SA, 53-57 Perikleous str., 153 44, Gerakas, Athens, Greece Tel: (210) 6831632 Fax: (210) 6836540
STOPAREN.
Pharmaceutical Form |
---|
Dry powder and solvent for solution for injection. |
STOPAREN 0.5g/VIAL (IV+IM): Each vial contains 0.524g of cefotaxime sodium equivalent to 500mg of cefotaxime.
STOPAREN 1g/VIAL (IV): Each vial contains 1.048g of cefotaxime sodium equivalent to 1g of cefotaxime.
STOPAREN 1g/VIAL (IM): Each vial contains 1.048g of cefotaxime sodium equivalent to 1g of cefotaxime.
For a full list of excipients, see section 5.1.
Active Ingredient | Description | |
---|---|---|
Cefotaxime |
Cefotaxime exerts its action by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thereby inhibiting cell wall synthesis. |
List of Excipients |
---|
None. |
Cefotaxime is supplied in Type III glass vials, closed with a rubber stopper.
STOPAREN 500mg (IM+IV): BTx1 vial + 1 ampoule solvent (2ml).
STOPAREN 1g (IV): BTx 1 vial + 1 ampoule solvent (4ml).
STOPAREN 1g (IM): BTx 1 vial + 1 ampoule solvent (4ml).
ANFARM HELLAS SA, 53-57 Perikleous str., 153 44, Gerakas, Athens, Greece
Tel: (210) 6831632
Fax: (210) 6836540
STOPAREN 500mg (IV+IM): 42877/9-6-2008
STOPAREN 1g (IV): 69858/10/12-5-2011
STOPAREN 1g (IM): 69859/10/12-5-2011
28-4-1987 / 9-6-2008
Drug | Countries | |
---|---|---|
STOPAREN | Lithuania, Malta |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.